Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ ...
Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...
Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.
Incidence of stroke within 72 hours after TAVI or before discharge, if sooner, came out a similar 2.1% with and 2.2% without ...
Sensydia, a clinical-stage non-invasive cardiac assessment company, announced today that University of Minnesota investigators presented positive clinical findings from a recent study evaluating the ...
Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...
Advances in PCI over the past decade mean the procedure can now approximate results only previously achieved with open-heart bypass surgery, new data show.
A decade after the first introduction of angiography-derived fractional flow reserve (FFR), we are now entering an era in which simplified image-derived solutions could replace invasive assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback